Established in 1993, MBL International Corporation (MBLI) is a leading life science company focused on providing high quality, innovative, solutions-based products for both life science research and clinical diagnostics. Their products are used widely in academic research institutions, pharmaceutical and biotechnology companies, government agencies as well as hospital and reference laboratories.
The MBLI product range can be divided into five distinct categories:
Life Science Research
MBLI develops, manufactures, and markets a broad portfolio of monoclonal and polyclonal antibodies, fluorescent and recombinant proteins and ELISA kits for research related to allergy, apoptosis, autophagy, cancer, epigenetics, immunology, and neuroscience.
MHC Tetramers: Directly Measure Antigen-Specific T Cells
MBLI has a wide portfolio of immune monitoring research products including tetramer technology for vaccine development, rapid T-cell detection and quantification in the pharmaceutical industry or bioresearch industry.
Drug Discovery Tools
MBL International Corporation offers fluorescent protein-based drug discovery tools for use in living cells. Their novel technology, Fluoppi, can visualise Protein-Protein Interaction (PPI) of interest in living cells. Moreover, other product offering such as Keima-Red and FUCCI, can visualise autophagy/mitophagy and cell cycle respectively. These technologies are applicable for cell-based high-throughput drug screening.
Detection of Autoimmune Diseases
Autoimmune diseases are classified into systemic autoimmune disease and organ-specific autoimmune disease. MBLI offers a wide variety of ELISA and immunofluorescence assays (IFA) for the detection of disease-related autoantibodies including anti-nuclear antibodies and anti-desmosomal structural protein antibodies.